330 related articles for article (PubMed ID: 31816084)
21. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.
Kostine M; Rouxel L; Barnetche T; Veillon R; Martin F; Dutriaux C; Dousset L; Pham-Ledard A; Prey S; Beylot-Barry M; Daste A; Gross-Goupil M; Lallier J; Ravaud A; Forcade E; Bannwarth B; Truchetet ME; Richez C; Mehsen N; Schaeverbeke T;
Ann Rheum Dis; 2018 Mar; 77(3):393-398. PubMed ID: 29146737
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
23. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding.
Daoussis D; Kraniotis P; Filippopoulou A; Argiriadi R; Theodoraki S; Makatsoris T; Koutras A; Kehagias I; Papachristou DJ; Solomou A; Kalofonos H; Liossis SN
Rheumatology (Oxford); 2020 May; 59(5):1041-1050. PubMed ID: 32344435
[TBL] [Abstract][Full Text] [Related]
24. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.
Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U
Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290
[TBL] [Abstract][Full Text] [Related]
25. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
26. [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy].
Verspohl SH; Schulze-Koops H; Heine A; Schäfer VS
Z Rheumatol; 2020 Oct; 79(8):797-808. PubMed ID: 32926217
[TBL] [Abstract][Full Text] [Related]
27. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.
Ibraheim H; Perucha E; Powell N
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii17-vii28. PubMed ID: 31816081
[TBL] [Abstract][Full Text] [Related]
28. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
[TBL] [Abstract][Full Text] [Related]
29. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
[TBL] [Abstract][Full Text] [Related]
31. Rheumatic Complications of Immune Checkpoint Inhibitors.
Ghosh N; Bass AR
Med Clin North Am; 2021 Mar; 105(2):227-245. PubMed ID: 33589099
[TBL] [Abstract][Full Text] [Related]
32. Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis.
Veccia A; Kostine M; Tison A; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Caffo O; Paolazzi G; Bortolotti R; Cornec D; Berti A
Joint Bone Spine; 2022 Jul; 89(4):105403. PubMed ID: 35508288
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
34. Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.
Mullenix C; Ballman M; Chen H; Swift S; McAdams MJ; Tsai YT; Donahue RN; Poretta T; Gupta S; Loehrer PJ; Schlom J; Gulley JL; Rajan A
Oncologist; 2022 Apr; 27(4):e353-e356. PubMed ID: 35380721
[TBL] [Abstract][Full Text] [Related]
35. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy.
Calabrese LH; Calabrese C
Curr Opin Rheumatol; 2020 Mar; 32(2):175-183. PubMed ID: 31922970
[TBL] [Abstract][Full Text] [Related]
36. Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy.
Dey A; Manolios N; Long GV; Carlino MS; Kefford R; Schrieber L
Intern Med J; 2022 May; 52(5):818-827. PubMed ID: 33135853
[TBL] [Abstract][Full Text] [Related]
37. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].
Benesova K; Leipe J
Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
Tocut M; Brenner R; Zandman-Goddard G
Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064
[TBL] [Abstract][Full Text] [Related]
39. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.
Lee KA; Kim HR; Yoon SY
Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065
[TBL] [Abstract][Full Text] [Related]
40. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
